Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Oct 18, 2001
SAN DIEGO, Oct. 18 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of $3.5 million for the quarter ended September 30, 2001, a 50% increase over third quarter 2000 revenues, and $12.2 million for the nine months ended September 30, 2001, a 238% increase over the nine months ended September 30, 2000. ...
Oct 2, 2001
SAN DIEGO, Oct 2, 2001 /PRNewswire via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet third quarter conference call on Thursday, October 18, 2001 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, c...
Aug 31, 2001
SAN DIEGO, Aug 31, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet conference call on Wednesday September 5, 2001 at 4:15 p.m. Eastern Time (1:15 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, chief financial officer...
Aug 20, 2001
SAN DIEGO, Aug 20, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA); ("Arena") today announced the signing of a license agreement with TaiGen Biotechnology Co., Ltd. ("TaiGen"), a privately-held biopharmaceutical organization located in Taipei, Taiwan. Under the terms of the agreement, TaiGen has the right to select validated scr...
Jul 23, 2001
SAN DIEGO, Jul 23, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of $3.3 million for the quarter ended June 30, 2001, a 158% increase over second quarter 2000 revenues, and $8.7 million for the six months ended June 30, 2001, a 576% increase over the six months ended June 30, 2000. Increased revenues in...
Jul 9, 2001
SAN DIEGO, July 9 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with the ICI group to apply Arena's proprietary CART technology to olfactory and gustatory G protein-coupled receptors (GPCRs). The initial stage of the research will last at least six months and Arena int...
Jul 5, 2001
SAN DIEGO, Jul 5, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet second quarter conference call on Monday, July 23, 2001 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, chief financial...
Jul 2, 2001
SAN DIEGO, Jul 2, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriting group managed by Thomas Weisel Partners LLC, Dain Rauscher Wessels, ABN AMRO Rothschild LLC and Lazard Freres & Co. LLC., have exercised their over-allotment option in connection with Arena's June 21, 2001 secondary offeri...
Jun 22, 2001
SAN DIEGO, June 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its follow-on offering of 5,000,000 shares of its common stock was priced on June 21, 2001 at $27.50 per share. Of the 5,000,000 shares, Arena offered 4,000,000 shares and two selling stockholders offered a total 1,000,000 shares. Arena...
Jun 5, 2001
SAN DIEGO, June 5 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed follow-on offering of 5,000,000 shares of its common stock. Of the 5,000,000 offered shares, Arena will offer 4,000,000 shares and two sellin...
May 8, 2001
NEW YORK--(BUSINESS WIRE)--May 8, 2001--The Wall Street Transcript has published an in-depth interview with Jack Lief, CEO of Arena Pharmaceuticals (Nasdaq:ARNA), in which he talks at length about the company's future. Click here to listen to a live webcast for the RBC Dain Rauscher Wessels Biotechnology "Gene To Drugs"...
Apr 25, 2001
SAN DIEGO--(BW HealthWire)--April 25, 2001-- The Collaborative Research Program Will Begin Immediately, and Arena's Purchase of $2 Million of Axiom Preferred Stock Expected to be Completed by the End of May 2001 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") and Axiom Biotechnologies Inc. ("Ax...
Apr 17, 2001
SAN DIEGO, April 17 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported results for the quarter ended March 31, 2001. During the first quarter 2001, the Company's revenues increased by $1.3 million over the previous quarter to record revenues of $5.4 million versus no revenues for the first quarter of 2000. Reve...
Apr 3, 2001
SAN DIEGO, April 3 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it will host both a telephone and internet first quarter conference call on Tuesday, April 17, 2001 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, ...
Mar 26, 2001
SAN DIEGO, March 26 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has entered into a receptor-discovery research collaboration with Taisho Pharmaceutical Co., Ltd. Phase I of the collaboration is directed toward identification studies for a receptor of interest to Taisho. Although the endogenous l...
= add release to Briefcase